
FDA Grants Full Approval to Braftovi Combination for First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
The agency converted Braftovi’s accelerated approval to full approval after Phase III BREAKWATER data demonstrated significant improvements in progression-free and overall survival in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer.




















